Medication adherence and persistence are often treated as questions of patient behaviour, but in claims and electronic health record (EHR) data they are also measurement problems. These databases record prescriptions, dispensings and reimbursed claims, not whether a medicine was taken, so the definitions and processing rules used to estimate exposure can change the result. This video explains how adherence and persistence are measured in real-world data and which analytical choices most affect the estimates.
WHAT THIS VIDEO COVERS
• The difference between adherence and persistence, and why a patient can score well on one and poorly on the other
• Why datasets that start at dispensing can miss primary adherence entirely
• What claims and EHR data each show about medicine use, and how clinical context can change the meaning of a treatment gap
• How medication possession ratio (MPR) and proportion of days covered (PDC) differ, and the choices both still depend on, such as overlapping supplies after a dose change
• How grace periods, censoring and an 80% adherence cut-off can classify similar patients differently
Two well-conducted analyses of the same records can produce different estimates if their rules differ. Starting from a precise research question and documenting how the measure is built makes those estimates easier to interpret and compare.
Quanticate’s statistical consultancy team supports sponsors with the design, analysis, and interpretation of studies using longitudinal claims and EHR databases, including drug adherence and persistence definitions, treatment gap rules, PDC and MPR approaches, censoring decisions, and reporting frameworks. If you are using real-world data to assess medication use over time, or need support to define and justify adherence measures for your study, request a consultation today.
Bring your drugs to market with fast and reliable access to experts from one of the world’s largest global biometric Clinical Research Organizations.
© 2026 Quanticate